Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Profit After Tax: 2009-2024

Historic Profit After Tax for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$56.4 million.

  • Anika Therapeutics' Profit After Tax rose 89.39% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year increase of 65.43%. This contributed to the annual value of -$56.4 million for FY2024, which is 31.79% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Profit After Tax is -$56.4 million, which was up 31.79% from -$82.7 million recorded in FY2023.
  • Anika Therapeutics' Profit After Tax's 5-year high stood at $4.1 million during FY2021, with a 5-year trough of -$82.7 million in FY2023.
  • Over the past 3 years, Anika Therapeutics' median Profit After Tax value was -$56.4 million (recorded in 2024), while the average stood at -$51.3 million.
  • In the last 5 years, Anika Therapeutics' Profit After Tax skyrocketed by 117.24% in 2021 and then slumped by 459.43% in 2022.
  • Anika Therapeutics' Profit After Tax (Yearly) stood at -$24.0 million in 2020, then skyrocketed by 117.24% to $4.1 million in 2021, then tumbled by 459.43% to -$14.9 million in 2022, then slumped by 456.34% to -$82.7 million in 2023, then spiked by 31.79% to -$56.4 million in 2024.